Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS

OBJECTIVES: To report the final results of the 2‐year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry®/BAY 81–8973) used in standard clinical practice in patients with moderate‐to‐severe haemophilia A. METHODS: TAURUS (NCT02830477) is a phase 4, multinational, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Cristina, Fuh, Beng, Le, Phu Quoc, Maes, Philip, Berrueco, Rubén, Mingot‐Castellano, Eva Maria, von Mackensen, Sylvia, Tueckmantel, Claudia, Cabre‐Marquez, Jose Francisco, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092432/
https://www.ncbi.nlm.nih.gov/pubmed/36192847
http://dx.doi.org/10.1111/ejh.13876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092432/
https://www.ncbi.nlm.nih.gov/pubmed/36192847
http://dx.doi.org/10.1111/ejh.13876

Ejemplares similares